On September 26, 2023, Nexus Pharmaceuticals, LLC announced that it had received approval from the U.S. Food and Drug Administration (FDA) for Fluorescein Injection, USP. Nexus Pharmaceuticals is a maker of generic drugs....more
The “Orange Book”, more formally known as Approved Drug Products with Therapeutic Equivalence Evaluations, identifies U.S. Food and Drug Administration (FDA) approved drug products as well as any related patent and...more
On November 7, 2016, the U.S. Supreme Court declined to review an appeal from a Third Circuit decision finding that a settlement between GlaxoSmithKline (GSK) and Teva Pharmaceutical Industries Ltd. (Teva) involving the...more
11/15/2016
/ Anti-Competitive ,
Antitrust Violations ,
Appeals ,
Denial of Certiorari ,
FTC v Actavis ,
Generic Drugs ,
GlaxoSmithKline ,
No-AG Agreement ,
Pay-For-Delay ,
Popular ,
Product Exclusivity ,
Reverse Payment Settlement Agreements ,
Rule-of-Reason Analysis ,
SCOTUS ,
Solicitor General ,
Teva Pharmaceuticals